PMID-35013352 – NNMT Inhibition and Gut Microbiome in DIO Mice
Dimet-Wiley A, Golovko G, Watowich SJ, Bhatt DK, Neelakantan H. Nicotinamide N-methyltransferase inhibition with 5-amino-1-methylquinolinium and dietary intervention modulates the gut microbiome in diet-induced obese mice. Sci Rep. 2022;12(1):97.
Quick Reference
| Property | Value |
|---|---|
| PMID | 35013352 |
| DOI | 10.1038/s41598-021-03670-5 |
| Year | 2022 |
| Journal | Scientific Reports |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Diet-induced obese (DIO) C57BL/6 mice, combined pharmacological and dietary interventions |
| Peptide(s) Studied | 5-Amino-1MQ |
Key Findings
- 5-Amino-1MQ treatment combined with transition to a low-fat diet produced distinct and beneficial gut microbiome changes in DIO mice
- Significant increase in Lactobacillus species — associated with improved metabolic health and reduced inflammation
- Significant decrease in Erysipelatoclostridium — a genus linked to metabolic dysfunction and obesity
- Microbiome modulation represents an additional mechanism of action for 5-Amino-1MQ beyond direct NNMT inhibition
- The combination of pharmacological NNMT inhibition with dietary intervention was more effective than either alone
- Alpha and beta diversity analyses revealed meaningful shifts in microbial community structure
Study Design
DIO mice were treated with 5-Amino-1MQ and/or transitioned from a high-fat to a low-fat diet. Fecal samples were collected at multiple time points for 16S rRNA gene sequencing. Microbial community composition, alpha diversity (Shannon index, observed OTUs), and beta diversity (UniFrac distances) were analyzed. Differential abundance testing identified specific taxa altered by treatment.
Limitations
- Mouse gut microbiome has limited direct translatability to human microbiome
- Dietary change (HFD to LFD) is a confounding variable — difficult to isolate 5-Amino-1MQ's independent effect on microbiome
- 16S rRNA sequencing provides genus-level resolution but limited functional information
- No measurement of microbial metabolites (short-chain fatty acids, etc.) to link microbiome changes to metabolic outcomes
- No assessment of whether microbiome changes are cause or consequence of weight loss
Clinical Relevance
This study adds an important dimension to the 5-Amino-1MQ mechanism of action story. Gut microbiome modulation is increasingly recognized as a mediator of metabolic health, and many patients seeking weight management also have dysbiotic gut profiles. The increase in Lactobacillus and decrease in obesity-associated taxa suggest that 5-Amino-1MQ may have synergistic benefits when combined with dietary changes — a scenario typical of clinical practice. This finding may also support the use of 5-Amino-1MQ in patients with GI-related metabolic dysfunction.
Related
#research #animal-in-vivo #5-Amino-1MQ #evidence-level-V